The companies collaborated to evaluate the efficacy & safety of IDE397 (MAT2A inhibitor) + AMG 193 (MTA-cooperative inhibitor of PRMT5) in a P-I trial for solid tumors with MTAP deletion. Both companies obtain all commercial rights to compounds as monothx. or combination therapies
Amgen will sponsor the P-I trial & will receive IDE397 drug supply. IDEAYA will lead the early clinical development of IDE397 with GSK. If GSK exercises its option, it will lead to later-stage development of IDE397
Both companies will share the costs of the study & will oversee the clinical development of the combination therapy. IDEAYA has initiated the P-I study of IDE397 as monothx. & in combination with docetaxel in NSCLC, paclitaxel in esophagogastric cancer & pemetrexed in NSCLC
Ref: PRNewswire | Image: IDEAYA
